Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152600 | 0.91 | PDE4B (0.40) | TSHRALDH1A1 | |
| SCHEMBL4140801 | 0.89 | HRH3 (0.34) | ALDH1A1KCNH2HRH3 | |
| SCHEMBL4145313 | 0.87 | CRHBP (0.44) | ALDH1A1KCNH2HRH3 | |
| SCHEMBL4136740 | 0.86 | ADORA1 (0.39) | TSHRALDH1A1ADORA1ABCB1 | |
| SCHEMBL4139873 | 0.86 | NAAA (0.46) | ALDH1A1HRH3 | |
| SCHEMBL4143136 | 0.85 | OPRM1 (0.40) | ALDH1A1KCNH2HRH3 | |
| SCHEMBL4128730 | 0.85 | OPRM1 (0.40) | ALDH1A1KCNH2HRH3 | |
| SCHEMBL4143141 | 0.85 | OPRM1 (0.40) | ALDH1A1KCNH2HRH3 | |
| SCHEMBL4128728 | 0.85 | OPRM1 (0.40) | ALDH1A1KCNH2HRH3 | |
| SCHEMBL4128725 | 0.85 | OPRM1 (0.40) | ALDH1A1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | L3MBTL1 3712/4885TSHR 154/4885ALDH1A1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.